Zenalpha is a drug owned by DECHRA, LTD. It is protected by 2 US drug patents filed in 2035. All patents are active. Details of Zenalpha’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US10058538 | 08 Nov, 2035 | Active |
Exclusivity Information
Zenalpha holds 1 exclusivity out of which 0 have expired. Its last outstanding exclusivity is set to expire in 2027. Details of Zenalpha's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE | Mar 30, 2027 |
About Zenalpha
Zenalpha is a drug
owned by DECHRA, LTD.
Zenalpha uses
Medetomidine Hydrochloride, Vatinoxan Hydrochloride as the active
ingredients.
Active Ingredient:
Zenalpha uses
Medetomidine Hydrochloride,
Vatinoxan Hydrochloride
as the active ingredients.
Check out other Drugs and Companies using
Medetomidine Hydrochloride, Vatinoxan Hydrochloride ingredient.